Vemurafenib + fotemustin clinically active in BRAF-refractory melanoma
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
The combination of vemurafenib plus fotemustine has clinical activity and manageable toxicity in patients with BRAF-mutated metastatic melanoma who experienced systemic progression while receiving single-agent BRAF inhibitor therapy.
Phase 2 single-group study conducted at 2 centers that investigated the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression while receiving a prior single-agent BRAF inhibitor.
31 patients with BRAF-mutated unresectable stage IIIC or stage IV melanoma with systemic progressive disease while receiving single-agent vemurafenib treatment were included in the study.
16 patients had brain metastases at enrollment into the trial.
Median PFS was 3.9 mo, and 19 patients (61.3%) achieved disease control; there was 1 complete respons...